Memantine Evolugen

Memantine hydrochloride, the active ingredient in Memantine Evolugen, is a NMDA receptor antagonist presented as a tablet for oral use. It is indicated for the treatment of Alzheimer’s disease in adults and helps to reduce excitotoxic neuronal damage.

GNH USA supplies Memantine Evolugen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine Evolugen is a NMDA‑receptor antagonist used in the management of neurodegenerative conditions, primarily Alzheimer’s disease.

- Alzheimer’s disease: improves cognition, global functioning and daily activities in patients with mild to moderate disease. - Vascular dementia (off‑label in some regions): may provide modest benefit in cognition when combined with standard therapy. - Frontotemporal dementia (off‑label): occasionally used to address behavioral symptoms, though evidence is limited.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Headache: transient, often resolves without intervention. - Constipation: reduced bowel movements, may require dietary adjustment. - Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects: - Seizures: new‑onset convulsive episodes requiring immediate medical attention. - Allergic reactions: rash, pruritus, or angioedema indicating hypersensitivity. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Suicidal thoughts: emergence of depressive ideation or self‑harm urges. - Cardiac arrhythmia: irregular heartbeat potentially requiring cardiology evaluation.

Before initiating Memantine Evolugen, clinicians should consider several safety aspects.

- Renal impairment: adjust dose or monitor renal function closely. - Hepatic impairment: use with caution; monitor liver enzymes. - History of seizures: assess risk, as memantine may lower seizure threshold. - Concomitant NMDA agonists: avoid combined use due to antagonistic interaction. - Pregnancy: safety category unknown; weigh potential benefits against risks. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Memantine may interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - NMDA agonists (e.g., D‑cycloserine): may counteract memantine’s therapeutic effect. - Amantadine: combined NMDA antagonism can increase risk of neuropsychiatric events.

Moderate Interactions (Monitor Closely): - Acetylcholinesterase inhibitors (e.g., donepezil): monitor for additive cognitive effects. - CNS depressants (e.g., benzodiazepines): may enhance sedation. - Diuretics (e.g., furosemide): monitor electrolytes and renal function.